Eli Lilly (LLY) — CaeTrader

Eli Lilly LLY Pharma

38.0 Score -3.3 (24h) • -13.1 (7d)

Updated 0m ago

StockBot · TradingView·Yahoo Finance·SEC Filings

Price History

Candle

RSI (14)

MACD (12, 26, 9)

ADX (14)

Score Guide

0 Bearish 50 Neutral 100 Bullish

1 Bullish1 Bearish5 Neutral

Analyst Ratings

77%

31 analysts

Buy

77%

Hold

19%

Sell

Consensus: Buy → stable

Key Financials

Price $961.36

Mkt Cap $860.24B

P/E 34.2

Beta 0.5

EPS $28.13

Div Yield 0.65%

Low $850 Mean $1,202 High $1,500

Current: $961.36

Technical Indicators

RSI (1D)

53.0

RSI (1W)

48.9

ADX (1D)

18.7

Trend (1D)▲ Bullish

Trend (1W)Neutral

Strategy Signals

TTM SqueezeOff

Heiken Ashi▼ Bearish ×1

Composite DivNone

Swing StructureNone

AVWAPNear

Fundamentals

Volume Ratio 0.47×

52W Position 67%

Short Interest0.9%

Sentiment +0.29

Latest News

Yahoo Finance Video · 5h ago +0.17

GLP-1 battle heats up between Eli Lilly and Novo Nordisk

BMO Capital Markets Managing Director, BioPharma Equity Research Evan Seigerman joins Julie Hyman on Market Catalyst to discuss the battle for GLP-1 dominance between Novo Nordisk (NVO) and Eli Lilly (LLY).

Investor's Business Daily · 56m ago 0.14

How This Eli Lilly-Tied IPO Stock Fared In Its First Quarter

IPO stock Omada Health easily beat first-quarter sales views Thursday, and announced a deal with drug titan Eli Lilly. But shares fell Friday.

Investor's Business Daily · 1h ago -0.61

Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off

Eli Lilly is just wrapping up trials of its retatrutide, but consumers already are flocking to black-market versions. Can Lilly compete with copies of its own drug?

TheStreet · 1h ago 0.10

Early Eli Lilly stock investors now earn a 9% dividend yield-on-cost

There's a reason the world's most patient investors love dividend stocks. Market movements heavily influence a stock's capital-gains potential in a given year. But dividends are usually paid whether the broader market is up or down, and that dependability is a big reason to factor them in when ...

Zacks · 4h ago -0.18

Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus

NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.

Motley Fool · 7h ago +0.17

Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.

The competition is far behind.

MarketBeat · 8h ago -0.18

Omada Health Q1 Earnings Call Highlights

Omada Health (NASDAQ:OMDA) reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA alongside a raised full-year outlook. On the earnings call, Co-Founder and CEO Sean D

Manufacturing Dive · 9h ago +0.71

Lilly to invest extra $4.5B across Indiana manufacturing

The Indianapolis-based company expanded its spend to ensure it can meet growing demand for genetic therapies and weight-loss drugs.

Insider Monkey · 9h ago +0.35

Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for the next 15 years. On May 7, Eli Lilly executed its largest bond issuance to date, selling $9 billion in investment-grade debt to fund a recent surge in acquisitions. The offering, which initially targeted $8 billion, saw high investor demand following […]

Simply Wall St. · 10h ago -0.97

Eli Lilly's (NYSE:LLY) Earnings Are Weaker Than They Seem

Eli Lilly and Company's ( NYSE:LLY ) stock was strong after they recently reported robust earnings. We did some...